Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

The respiratory syncytial virus (RSV) vaccine triggered strong immune responses among people aged 60 years and older during ...

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this PreF protein, as do other candidates in the late-stage ...

Abrysvo has also been approved as a maternal vaccine to prevent RSV in newborns, an indication that GSK abandoned for Arexvy, but in that category it has to compete with Sanofi and AstraZeneca’s ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

Snopes tried to discredit research as a "rumor" when journalist received early results from conference call between researchers and study participants. Spike still detectable in some participants ...